From the Infection Control Unit (J-RZ), Necker University Hospital Paris, Assistance Publique–Hôpitaux de Paris, Paris, France; INSERM U823 (J-FT, AV), Albert Bonniot Research Center, Team 11: “Outcome of Cancers and Critical Illnesses,” La Tronche, France; the Medical–Surgical ICU (MG-O, AF), Saint Joseph Hospital, Paris, France; the Surgical Intensive Care Unit (AD-D), Antoine Béclère Hospital, Assistance Publique-Hôpitaux de Paris, Clamart, France; the Medical Intensive Care Unit (J-FT, YD), Albert Michallon Teaching Hospital, Joseph Fournier University, Grenoble, France; the Medical ICU (BS), Clermont-Ferrand University Hospital, Clemont-Ferrand, France; the Medical ICU (HH), Jean Verdier University Hospital, Bondy, France; the Medical–Surgical ICU (DG-T), Gonesse Hospital, Gonesse, France; the Surgical ICU (BA), Edouard Herriot University Hospital, Lyon, France; the Medical Intensive Care Unit (EA), Saint Louis University Hospital, Paris, France; and the Physiology Department (CA), Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, the University of René Descartes, Paris, France.
This article was written on behalf of the OUTCOMEREA Study Group.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.ccmjournal.com).
Dr. Azoulay consulted with Pfizer (France) and received honoraria/speaking fees and a grant from Pfizer (Gilead). The remaining authors have not disclosed any potential conflicts of interest.
For information regarding this article, E-mail: [email protected]